Cardioxane

Known as: Cardioxan 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1991-2012
02419912012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
The authors conducted a retrospective study to determine whether dexrazoxane (ICRF-187) would reduce late anthracycline-induced… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2000
2000
The aim of the study was an evaluation of circulatory system functions in patients with Wilms' tumour who underwent the multidrug… (More)
Is this relevant?
1998
1998
BACKGROUND Reactive oxygen species produced during metabolism of adriamycin are purported to play an important role in the… (More)
Is this relevant?
1997
1997
The tolerance of cardioxan (JCRF-187, dexrazoxan), an ethylenediamine tetra-acetic acid analog and a Chiron Company product… (More)
Is this relevant?
1997
1997
A cardiotoxic effect induced by adriamycin (by repeated i.v. administration to experimental rats in 7-day intervals of… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
Is this relevant?
1996
1996
The clinical use of anthracyclines and related antitumor agents is limited by their cumulative dose-related cardiac toxicity… (More)
Is this relevant?
Review
1996
Review
1996
The dose-limiting toxicity of the widely used anticancer agent, doxorubicin, is a destructive, irreversible and progressive… (More)
Is this relevant?
1995
1995
A study of cardioprotection with ICRF-187 (Cardioxane, Eurocetus) has been performed in 35 patients with metastatic breast cancer… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
1995
1995
From January 1991 to August 1993, 237 women with metastatic breast cancer were recruited into a multicentric phase II clinical… (More)
Is this relevant?
1995
1995
1. The clinical use of the antitumour agent, doxorubicin, is largely limited by the development of a cumulative dose-related… (More)
Is this relevant?